Author(s)

Chuhan Xiong, Jiaying Yang, Ya Zhang

Corresponding Author

Chuhan Xiong

ABSTRACT

In the global female population, breast cancer is common cancer with high morbidity and high mortality, and the number of patients is increasing year by year. The current treatment is still based on resection, chemotherapy and other programs. However, these methods can have considerable side effects or altogether remove breast cancer lesions and lead to recurrence and further development. Immunotherapy refers to a treatment that artificially enhances or suppresses the patient's immune function when the immune function of the patient is in a low or hyperactive state to activate the patient's immune system and rely on the autoimmune mechanism to attack cancer cells. More and more trials have proved that immunotherapy has great potential in treating breast cancer in recent years. Adjuvant treatments can improve the survival rate of patients and are better than conventional programs such as chemotherapy. However, due to technical barriers, the development of breast cancer immunotherapy is still immature. This article will describe four kinds of standard cellular immunotherapy: TILs therapy, TAR-T therapy, CAR-T therapy and NK cell therapy and their latest research progress in breast cancer treatment.

KEYWORDS

Breast cancer, immunotherapy, TILs therapy, TCR-T therapy, CAR-T therapy, NK therapy